A detailed history of Roberts Glore & CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Roberts Glore & CO Inc holds 4,155 shares of VRTX stock, worth $1.87 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
4,155
Previous 4,342 4.31%
Holding current value
$1.87 Million
Previous $2.04 Million 5.06%
% of portfolio
0.57%
Previous 0.62%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $86,020 - $94,580
-187 Reduced 4.31%
4,155 $1.93 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $95,452 - $117,983
-243 Reduced 5.3%
4,342 $2.04 Million
Q1 2024

May 09, 2024

SELL
$407.69 - $446.08 $110,891 - $121,333
-272 Reduced 5.6%
4,585 $1.92 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $96,383 - $115,401
-281 Reduced 5.47%
4,857 $1.98 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $4,734 - $5,074
-14 Reduced 0.27%
5,138 $1.79 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $10,375 - $11,613
-33 Reduced 0.64%
5,152 $1.81 Million
Q1 2023

May 08, 2023

SELL
$283.23 - $323.1 $8,213 - $9,369
-29 Reduced 0.56%
5,185 $1.63 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $94,872 - $106,731
-332 Reduced 5.99%
5,214 $1.51 Million
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $28,752 - $32,080
-105 Reduced 1.86%
5,546 $1.61 Million
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $91,634 - $114,094
-390 Reduced 6.46%
5,651 $1.59 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $68,325 - $86,251
386 Added 6.83%
6,041 $1.33 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $1.03 Million - $1.15 Million
5,655 New
5,655 $1.03 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Roberts Glore & CO Inc Portfolio

Follow Roberts Glore & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.